Chicago Partners Investment Group LLC Has $476,000 Holdings in Zoetis Inc. (NYSE:ZTS)

Chicago Partners Investment Group LLC increased its holdings in Zoetis Inc. (NYSE:ZTS) by 11.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,518 shares of the company’s stock after acquiring an additional 265 shares during the period. Chicago Partners Investment Group LLC’s holdings in Zoetis were worth $476,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Whittier Trust Co. grew its position in Zoetis by 3.2% in the 1st quarter. Whittier Trust Co. now owns 10,810 shares of the company’s stock worth $1,829,000 after purchasing an additional 332 shares in the last quarter. Whittier Trust Co. of Nevada Inc. grew its position in Zoetis by 8.0% in the 1st quarter. Whittier Trust Co. of Nevada Inc. now owns 2,792 shares of the company’s stock worth $472,000 after purchasing an additional 208 shares in the last quarter. Central Pacific Bank Trust Division bought a new stake in Zoetis in the 1st quarter worth about $509,000. Proficio Capital Partners LLC grew its position in Zoetis by 6.5% in the 1st quarter. Proficio Capital Partners LLC now owns 2,761 shares of the company’s stock worth $467,000 after purchasing an additional 169 shares in the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S grew its position in Zoetis by 58.6% in the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 41,931 shares of the company’s stock worth $7,095,000 after purchasing an additional 15,491 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Down 3.7 %

ZTS opened at $175.18 on Tuesday. The company has a 50 day moving average of $188.84 and a 200 day moving average of $179.03. The company has a market cap of $79.37 billion, a PE ratio of 34.28, a price-to-earnings-growth ratio of 2.78 and a beta of 0.90. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, topping the consensus estimate of $1.49 by $0.07. The company had revenue of $2.36 billion during the quarter, compared to the consensus estimate of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. Zoetis’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same period last year, the firm earned $1.41 EPS. On average, sell-side analysts expect that Zoetis Inc. will post 5.83 EPS for the current year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be issued a $0.432 dividend. This represents a $1.73 annualized dividend and a yield of 0.99%. The ex-dividend date of this dividend is Thursday, October 31st. Zoetis’s dividend payout ratio (DPR) is presently 33.66%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on ZTS shares. BTIG Research upped their price objective on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Argus raised shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. JPMorgan Chase & Co. increased their target price on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Stifel Nicolaus increased their target price on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday, September 18th. Finally, Piper Sandler increased their target price on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Zoetis presently has a consensus rating of “Buy” and an average price target of $221.44.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.